The case for & against
Bull & Bear analysis
Bearish
CVS Health Corporation (NYSE: CVS) operates as a diversified healthcare company that integrates pharmacy services, retail pharmacy, pharmacy benefit management (PBM), and health insurance through Aetna. Located at the intersection of healthcare delivery and consumer engagement, CVS seeks to improve healthcare accessibility and affordability, leveraging technology and innovation as key drivers. The company’s comprehensive model positions it as a leader in addressing current healthcare challenges, particularly in the context of rising drug prices and emerging health trends such as GLP-1 medications.
Bull says
- ↑Q1 revenue $100B, up 6% YoY across all segments
- ↑Adjusted EPS $2.57, +14% YoY; guide raised to $7.30–$7.50
- ↑Expanding GLP-1 support programs to capture weight-management demand
- ↑Heavy tech investments to evolve into a healthcare technology firm
- ↑Strong momentum factors and positive analyst revisions bolster sentiment
Bear says
- ↓P/E 44.97x vs 25.9x industry average, ~31% overvalued
- ↓Underlying medical cost trends remain elevated, pressuring profitability
- ↓Benefits segment lost 600K members; medical loss ratio 84.6%
- ↓Regulatory risks in PBM and Medicare Advantage rate setting
- ↓Weak profitability and growth factors raise return concerns
- ↓Low institutional ownership signals limited large-cap investor interest
Investment themes with CVS
High Dividend Yield↑ +0.32%
Companies paying above-average dividends
AVGO · JPM · XOM
Health Care Providers↓ -0.61%
UNH · CVS · HCA
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-07-2026neutral
Transcript signals
Bull points
- We generated over $100 billion of revenue, an increase of over 6% over the prior year quarter, driven by growth across all operating segments.
- Adjusted operating income of approximately $5.2 billion increased over 12% from the prior year quarter, primarily driven by an improvement in our healthcare benefits segment.
- We delivered adjusted EPS of $2.57, a meaningful increase of over 14% from the prior year quarter.
Bear points
- we still have a lot of clients that are actually discontinuing coverage for the obesity products of GLP-1s.
- The final rate notice that came out in April represented a step in the right direction towards greater sustainability but it remains insufficient to offset underlying medical cost trends. These trends remain above historical levels and for the past several years have pressured the entire industry.
- Tennessee that look to do something similar to what we saw in Arkansas. So really, two questions here. One, how are you navigating that? And two, kind of dovetailing into an earlier question, and David, what you just talked about with your client forum, Will we see meaningful changes due to some of these potential changes that could happen in trying to separate the different components of pharmacy, whether we think about specialty or the retail versus the PBM?
Read full transcript analysis ›